KRTX on NASDAQ

Karuna Therapeutics

Biopharmaceutical company.1

Price unavailable

Last updated Oct 19, 2026.

Overview

2009Founded1

Compare with Polomar Health Services, Inc., BioXcel Therapeutics, Inc. or Unicycive Therapeutics, Inc., or pick any stock.

  • TickerKRTX on NASDAQ1
  • Industrypharmaceutical industry1
  • HeadquartersBoston1
  • Websitekarunatx.com
  • Business address99 High Street, 26Th Floor, Boston, Ma 021103
  • Filer categoryLarge accelerated filer3

See how the biggest companies compare on our leaderboards

We are a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions. Our pipeline is primarily built on the broad therapeutic potential of our proprietary lead product candidate, KarXT (xanomeline-trospium), an oral modulator of muscarinic receptors that are located both in the central nervous system, or CNS, and various peripheral tissues. KarXT combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the CNS. We are initially developing KarXT for the treatment of acute psychosis in adults with schizophrenia, as well as for the treatment of psychosis in Alzheimer's disease, or AD.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-75654.0%Operating margin5
-66311.9%Net margin5
-93.9%Revenue growth, 20235
-34.6%Return on equity5
-$388.7MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Research and development100¢$364.1M
  • Income tax0¢$670.0K

Out of $654.0K in revenue.5 The company lost money this year.

Financial statements

Revenue65$654.0K in 2023
0$10.0M$20.0M$30.0M$40.0M2020: $0$020202021: $37.0M$37.0M20212022: $10.6M$10.6M2022−71%2023: $654.0K$654.0K2023−94%
Operating income7865-$494.8M in 2023+3310% since 2018
-$600.0M-$400.0M-$200.0M02018: -$14.5M-$14.5M20182019: -$45.4M-$45.4M2019+213%2020: -$71.8M-$71.8M2020+58%2021: -$143.9M-$143.9M2021+100%2022: -$289.7M-$289.7M2022+101%2023: -$494.8M-$494.8M2023+71%
Net income7865-$433.7M in 2023+2376% since 2018
-$600.0M-$400.0M-$200.0M02018: -$17.5M-$17.5M20182019: -$44.0M-$44.0M2019+151%2020: -$68.6M-$68.6M2020+56%2021: -$143.8M-$143.8M2021+110%2022: -$276.3M-$276.3M2022+92%2023: -$433.7M-$433.7M2023+57%
Fiscal year2017201820192020202120222023
Revenue$06$37.0M5$10.6M5$654.0K5
Research and development$11.5M7$24.5M8$43.4M6$128.2M5$224.2M5$364.1M5
Operating expenses$180.8M5$300.3M5$495.4M5
Operating income-$14.5M7-$45.4M8-$71.8M6-$143.9M5-$289.7M5-$494.8M5
Income before tax-$143.8M5-$274.9M5-$433.0M5
Income tax$07$08$43.0K6$6.0K5$1.4M5$670.0K5
Net income-$17.5M7-$44.0M8-$68.6M6-$143.8M5-$276.3M5-$433.7M5
Earnings per share-$2.596-$4.945-$8.745-$11.735
Earnings per share (diluted)-$2.596-$4.945-$8.745-$11.735
Shares (weighted, basic)29.1M shares531.6M shares537.0M shares5
Shares (weighted, diluted)29.1M shares531.6M shares537.0M shares5

Compare Karuna Therapeutics with another company

Leadership

Who has led Karuna Therapeutics, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. William Meury2023–2024

President

  1. William Meury2023–2024

Chief financial officer

  1. Troy A. Ignelzi2019–2023
2010201520202025
Board members and other officers (14)

Timeline

  1. Jan 5, 2023New chief executive William Meury becomes CEO13
  2. Jun 28, 2019Went public Listed on NASDAQ1
  3. 2009Founded Founded1

Filings

226 filings to the SEC since October 2021: 4 annual reports, 7 quarterly reports, 30 major events, 120 insider forms, 20 large holders, 45 other. The latest 20:

  1. Mar 28, 202415-12G EDGAR
  2. Mar 18, 20244 EDGAR
  3. Mar 18, 20244 EDGAR
  4. Mar 18, 20244 EDGAR
  5. Mar 18, 20244 EDGAR
  6. Mar 18, 20244 EDGAR
  7. Mar 18, 20244 EDGAR
  8. Mar 18, 20244 EDGAR
  9. Mar 18, 20244 EDGAR
  10. Mar 18, 20244 EDGAR
  11. Mar 18, 20244 EDGAR
  12. Mar 18, 20244 EDGAR
  13. Mar 18, 20244 EDGAR
  14. Mar 18, 20244 EDGAR
  15. Mar 18, 2024S-8 POS EDGAR
  16. Mar 18, 2024S-8 POS EDGAR
  17. Mar 18, 2024S-8 POS EDGAR
  18. Mar 18, 2024S-8 POS EDGAR
  19. Mar 18, 2024S-8 POS EDGAR
  20. Mar 18, 2024POSASR EDGAR

The 226 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

69 open-market trades by officers, directors and large owners since October 2021: 3 buys and 66 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Mar 8, 2024Brannan Stephen K.Chief Medical OfficerSale5,000$318.34$1.6MForm 4
Feb 8, 2024Brannan Stephen K.Chief Medical OfficerSale5,000$316.13$1.6MForm 4
Jan 8, 2024Brannan Stephen K.Chief Medical OfficerSale15,000$316.81$4.8MForm 4
Dec 8, 2023Brannan Stephen K.Chief Medical OfficerSale10,000$202.37$2.0MForm 4
Nov 8, 2023Brannan Stephen K.Chief Medical OfficerSale5,000$177.85$889.3KForm 4
Oct 9, 2023Brannan Stephen K.Chief Medical OfficerSale5,000$173.24$866.2KForm 4
Sep 8, 2023Brannan Stephen K.Chief Medical OfficerSale5,000$184.04$920.2KForm 4
Sep 1, 2023JONAS JEFFREY MDirectorSale13,809$187.93$2.6MForm 4
Aug 22, 2023Ignelzi Troy A.Chief Financial OfficerSale1,500$175.12$262.7KForm 4
Aug 8, 2023Brannan Stephen K.Chief Medical OfficerSale5,000$180.40$902.0KForm 4
Aug 1, 2023JONAS JEFFREY MDirectorSale13,810$195.81$2.7MForm 4
Jul 3, 2023OLSON LAURIE JDirectorSale1,000$215.65$215.7KForm 4
Jul 3, 2023JONAS JEFFREY MDirectorSale13,810$216.42$3.0MForm 4
May 23, 2023Ignelzi Troy A.Chief Financial OfficerSale9,000$223.41$2.0MForm 4
Apr 20, 2023Miller Andrew CraigPresident of R&DSale15,000$200.13$3.0MForm 4
Apr 18, 2023Miller Andrew CraigPresident of R&DSale30,000$200.16$6.0MForm 4
Apr 10, 2023Brannan Stephen K.Chief Medical OfficerSale5,000$176.88$884.4KForm 4
Apr 3, 2023OLSON LAURIE JDirectorSale1,000$181.02$181.0KForm 4
Mar 9, 2023Brannan Stephen K.Chief Medical OfficerSale5,000$189.51$947.5KForm 4
Feb 21, 2023Ignelzi Troy A.Chief Financial OfficerSale6,000$190.01$1.1MForm 4

All 69 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Members of Congress who traded it

1 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Apr 10, 2023Daniel S. GoldmanDemocratic, HouseSale$1,001 - $15,000Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35